Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
13 analysts have recently updated their ratings on ACADIA Pharmaceuticals (NASDAQ:ACAD), showing a mix of bullish to bearish sentiments. The average 12-month price target is now $35.31, up from $32.00, with a range from $25.00 to $42.00. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's market position and financial performance. ACADIA Pharmaceuticals, a biotech firm focusing on central nervous system disorders, has shown a notable revenue growth of 61.96% as of September 30, 2023, and has a strong market presence with a market capitalization above industry benchmarks.
February 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals has received mixed analyst ratings but shows a positive trend with an increased average price target of $35.31. The company's strong revenue growth and market presence are highlighted.
The mixed analyst ratings with a trend towards positive adjustments in price targets suggest a cautiously optimistic outlook for ACADIA Pharmaceuticals. The significant revenue growth and strong market capitalization further support a positive short-term impact on the stock price. The increase in the average price target reflects analysts' growing confidence in the company's financial health and market position.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100